Pacific Biosciences of California, Inc. (PACB) shareholders
Close on Nov 16, 2026Market cap $571.93MP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 33,445,993 | 10.80% | 13G (passive) | Oct 31, 2026 |
| Catherine D. Wood Joint filing with ARK Investment Management LLC (10.30%) | 30,924,103 | 10.30% | 13G (passive) amendment | Sep 30, 2025 |
| ARK Investment Management LLC Joint filing with Catherine D. Wood (9.59%) | 29,781,416 | 9.59% | 13G (passive) amendment | Jun 30, 2026 |
| Goldman Sachs & Co. LLC Joint filing with The Goldman Sachs Group, Inc. (7.60%) | 23,515,936 | 7.60% | 13G (passive) | Sep 30, 2026 |
| BlackRock, Inc. | 22,865,948 | 7.70% | 13G (passive) amendment | Mar 31, 2025 |
| Israel A. Englander Joint filing with Millennium Management LLC (6.00%), Millennium Group Management LLC (6.00%) | 16,443,656 | 6.00% | 13G (passive) | Dec 4, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PACB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 32,339,550 | 10.40% | $54.33M | +7,072,121 | 0.00% |
| ARK Investment Management LLC | 29,781,416 | 9.58% | $50.03M | −6,491,872 | 0.32% |
| Softbank Group Corp. | 20,451,570 | 6.58% | $34.36M | – | 0.19% |
| Vanguard Capital Management LLC | 13,397,934 | 4.31% | $22.51M | +620,485 | 0.00% |
| Geode Capital Management, LLC | 7,606,518 | 2.45% | $12.78M | +631,252 | 0.00% |
| Sumitomo Mitsui Trust Holdings, Inc. | 6,009,715 | 1.93% | $10.10M | −1,028,272 | 0.01% |
| Nikko Asset Management Americas, Inc. | 6,009,715 | 1.93% | $10.04M | −1,028,272 | 0.13% |
| State Street Corp | 5,961,175 | 1.92% | $10.01M | −160,541 | 0.00% |
| Point72 Asset Management, L.P. | 4,787,300 | 1.54% | $8.04M | +4,501,600 | 0.01% |
| Two Sigma Investments, LP | 4,242,599 | 1.36% | $7.13M | +732,986 | 0.01% |
| D. E. Shaw & Co., Inc. | 4,208,146 | 1.35% | $7.07M | +570,599 | 0.00% |
| Millennium Management LLC | 3,962,442 | 1.27% | $6.66M | −929,876 | 0.00% |
| Goldman Sachs Group Inc | 3,229,887 | 1.04% | $5.43M | +2,241,420 | 0.00% |
| Citadel Advisors LLC | 2,845,903 | 0.92% | $4.78M | +1,269,852 | 0.00% |
| Vanguard Portfolio Management LLC | 2,671,916 | 0.86% | $4.49M | −196,477 | 0.00% |
| Charles Schwab Investment Management Inc | 2,652,298 | 0.85% | $4.46M | +246,802 | 0.00% |
| Northern Trust Corp | 2,352,786 | 0.76% | $3.95M | +221,998 | 0.00% |
| Vanguard Fiduciary Trust Co | 2,187,627 | 0.70% | $3.68M | +201,144 | 0.00% |
| Susquehanna International Group, Llp | 2,129,263 | 0.69% | $3.58M | +410,098 | 0.00% |
| Longaeva Partners L.P. | 2,118,231 | 0.68% | $3.56M | New | 0.08% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 223 | 191M | 61.5% | 24 / 70 | 77 / 29 | 26M | 23M |
| Q1 2026 | 231 | 188M | 60.5% | 52 / 60 | 71 / 31 | 32M | 27M |
| Q4 2025 | 216 | 201M | 64.6% | 43 / 69 | 51 / 31 | 41M | 24M |
| Q3 2025 | 208 | 188M | 60.4% | 28 / 57 | 60 / 25 | 16M | 28M |
| Q2 2025 | 207 | 200M | 64.2% | 30 / 53 | 72 / 46 | 15M | 41M |
| Q1 2025 | 225 | 225M | 72.5% | 37 / 58 | 74 / 35 | 8M | 42M |
| Q4 2024 | 226 | 260M | 83.5% | 39 / 76 | 65 / 35 | 50M | 22M |
| Q3 2024 | 226 | 233M | 74.8% | 24 / 70 | 76 / 25 | 42M | 29M |
| Q2 2024 | 229 | 243M | 78.1% | 35 / 81 | 61 / 71 | 31M | 59M |
| Q1 2024 | 267 | 271M | 87.1% | 48 / 93 | 70 / 51 | 38M | 62M |
| Q4 2023 | 274 | 296M | 95.2% | 49 / 105 | 74 / 45 | 58M | 26M |
| Q3 2023 | 274 | 265M | 85.3% | 43 / 92 | 86 / 40 | 31M | 23M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
136 funds held PACB in Q2 2026, 78% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PACB | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Innovation ETF | 12,810,378 | 4.12% | $17.93M | 0.32% | Jul 31, 2026 |
| ARK Genomic Revolution ETF | 10,630,263 | 3.42% | $14.88M | 0.96% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 9,535,565 | 3.07% | $16.02M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 7,351,682 | 2.37% | $12.35M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 3,581,020 | 1.15% | $6.02M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 3,057,975 | 0.98% | $4.28M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 2,473,318 | 0.80% | $4.16M | 0.03% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 2,088,495 | 0.67% | $3.11M | 0.06% | May 29, 2026 |
| iShares Biotechnology ETF | 1,996,772 | 0.64% | $3.35M | 0.04% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,586,709 | 0.51% | $2.36M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,434,895 | 0.46% | $2.14M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,416,531 | 0.46% | $2.11M | 0.01% | May 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 1,067,651 | 0.34% | $1.49M | 0.05% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 766,110 | 0.25% | $1.14M | 0.01% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 685,461 | 0.22% | $959.65K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| William Meyer | See Remarks | 44,000 | 0.01% | Nov 13, 2026 |
| James R. Gibson II | See Remarks | 1,083,848 | 0.35% | Oct 8, 2026 |
| Oene Mark Van | See Remarks | 2,705,853 | 0.87% | Aug 18, 2026 |
| Michele Farmer | See Remarks | 305,948 | 0.10% | Mar 4, 2026 |
| Christian O. Henry | See Remarks | 3,581,813 | 1.15% | Mar 4, 2026 |
| Randall S. Livingston | Director | 22,821 | 0.01% | Jun 4, 2026 |
| William W. Ericson | Director | 4,890,013 | 1.57% | Jun 4, 2026 |
| Kathy Ordonez | Director | 403,037 | 0.13% | Jun 4, 2026 |
| Christopher Gibson | Director | 111,386 | 0.04% | Jun 4, 2026 |
| Christopher M. Smith | Director | 54,099 | 0.02% | Jun 4, 2026 |
| Marshall Mohr | Director | 132,821 | 0.04% | Jun 4, 2026 |
| John F. Milligan | Director | 132,821 | 0.04% | Jun 4, 2026 |
| Hannah Valantine | Director | 22,821 | 0.01% | Jun 4, 2026 |
| Lucy Shapiro | Director | 22,821 | 0.01% | Jun 6, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James R. Gibson II See Remarks | Oct 6, 2026 | Sale(10b5-1 plan) | −661,815 | $3.11 | $2.06M | 1,083,848 |
| James R. Gibson II See Remarks | Oct 6, 2026 | Option exercise | +500,000 | $1.18 | $590.00K | 1,745,663 |
| Oene Mark Van See Remarks | Aug 17, 2026 | Sale | −26,911 | $1.13 | $30.41K | 2,705,853 |
| Oene Mark Van See Remarks | Aug 10, 2026 | Award | +489,130 | – | – | 2,732,764 |
| Christopher Gibson Director | Apr 8, 2026 | Award | +57,473 | – | – | 111,386 |
| James R. Gibson II See Remarks | Apr 1, 2026 | Sale | −88,185 | $1.37 | $120.81K | 1,245,663 |
| Christopher Gibson Director | Mar 3, 2026 | Award | +53,913 | – | – | 53,913 |
| Oene Mark Van See Remarks | Mar 3, 2026 | Sale | −6,504 | $1.51 | $9.82K | 2,243,634 |
| Christian O. Henry See Remarks | Mar 3, 2026 | Sale | −12,497 | $1.51 | $18.87K | 3,581,813 |
| Michele Farmer See Remarks | Mar 3, 2026 | Sale | −2,979 | $1.51 | $4.50K | 305,948 |
| Oene Mark Van See Remarks | Feb 27, 2026 | Award | +500,000 | – | – | 2,242,638 |
| Christian O. Henry See Remarks | Feb 27, 2026 | Award | +920,810 | – | – | 3,594,310 |
| James R. Gibson II See Remarks | Feb 27, 2026 | Award | +333,848 | – | – | 1,333,848 |
| Michele Farmer See Remarks | Feb 27, 2026 | Award | +89,835 | – | – | 308,927 |
| Oene Mark Van See Remarks | Feb 18, 2026 | Sale | −55,107 | $1.63 | $89.82K | 1,742,638 |
| Michele Farmer See Remarks | Feb 18, 2026 | Sale | −14,952 | $1.63 | $24.37K | 219,092 |
| Christian O. Henry See Remarks | Feb 18, 2026 | Sale | −140,874 | $1.63 | $229.62K | 2,673,500 |
| Oene Mark Van See Remarks | Feb 17, 2026 | Sale | −129,790 | $1.58 | $205.07K | 1,797,745 |
| Michele Farmer See Remarks | Feb 17, 2026 | Sale | −35,215 | $1.58 | $55.64K | 234,044 |
| Christian O. Henry See Remarks | Feb 17, 2026 | Sale | −331,793 | $1.58 | $524.23K | 2,814,374 |
| Oene Mark Van See Remarks | Aug 18, 2025 | Sale | −26,836 | $1.31 | $35.16K | 1,920,035 |
| Michele Farmer See Remarks | May 19, 2025 | Sale | −5,195 | $1.00 | $5.20K | 269,259 |
| James R. Gibson II See Remarks | Mar 31, 2025 | Award | +1,000,000 | – | – | 1,000,000 |
| Christian O. Henry See Remarks | Mar 19, 2025 | Award | +920,810 | – | – | 3,146,167 |
| Oene Mark Van See Remarks | Mar 19, 2025 | Award | +449,176 | – | – | 1,946,871 |
| Michele Farmer See Remarks | Mar 19, 2025 | Award | +89,835 | – | – | 274,454 |
| Michele Farmer See Remarks | Mar 3, 2025 | Sale | −2,973 | $1.41 | $4.19K | 184,619 |
| Christian O. Henry See Remarks | Mar 3, 2025 | Sale | −12,497 | $1.41 | $17.62K | 2,225,357 |
| Oene Mark Van See Remarks | Mar 3, 2025 | Sale | −6,486 | $1.41 | $9.15K | 1,497,695 |
| Oene Mark Van See Remarks | Feb 18, 2025 | Sale | −100,773 | $1.88 | $189.45K | 1,496,681 |
| Christian O. Henry See Remarks | Feb 18, 2025 | Sale | −259,909 | $1.88 | $488.63K | 2,237,854 |
| Michele Farmer See Remarks | Feb 18, 2025 | Sale | −24,349 | $1.88 | $45.78K | 187,592 |
| Christopher M. Smith Director | Jan 30, 2025 | Award | +54,099 | – | – | 54,099 |
| Oene Mark Van See Remarks | Jan 10, 2025 | Sale | −34,405 | $2.03 | $69.84K | 1,597,454 |
| Susan G. Kim See Remarks | Sep 30, 2024 | Sale | −19,782 | $1.72 | $34.03K | 695,654 |
| Christian O. Henry See Remarks | Sep 16, 2024 | Sale | −98,907 | $1.75 | $173.09K | 2,497,763 |
| Jeff Eidel See Remarks | Aug 19, 2024 | Sale | −26,760 | $1.59 | $42.55K | 869,730 |
| Oene Mark Van See Remarks | Aug 16, 2024 | Sale | −38,011 | $1.66 | $63.10K | 1,630,815 |
| Lucy Shapiro Director | Jun 18, 2024 | Award | +22,821 | – | – | 22,821 |
| Marshall Mohr Director | Jun 18, 2024 | Award | +22,821 | – | – | 132,821 |
| William W. Ericson Director | Jun 18, 2024 | Award | +22,821 | – | – | 41,616 |
| Randall S. Livingston Director | Jun 18, 2024 | Award | +22,821 | – | – | 22,821 |
| Hannah Valantine Director | Jun 18, 2024 | Award | +22,821 | – | – | 22,821 |
| Kathy Ordonez Director | Jun 18, 2024 | Award | +22,821 | – | – | 403,037 |
| David W. Meline Director | Jun 18, 2024 | Award | +17,116 | – | – | 57,116 |
| John F. Milligan Director | Jun 18, 2024 | Award | +22,821 | – | – | 132,821 |
| Michele Farmer See Remarks | May 20, 2024 | Sale | −5,275 | $2.03 | $10.71K | 211,941 |
| Kathy Ordonez Director | Mar 15, 2024 | Option exercise | +324,515 | $2.90 | $941.09K | 343,110 |
| Kathy Ordonez Director | Mar 15, 2024 | Option exercise | +37,106 | $2.63 | $97.59K | 380,216 |
| David W. Meline Director | Mar 6, 2024 | Buy | +40,000 | $4.40 | $176.00K | 40,000 |
| Oene Mark Van See Remarks | Mar 4, 2024 | Sale | −9,186 | $4.87 | $44.74K | 1,668,826 |
| Michele Farmer See Remarks | Mar 4, 2024 | Sale | −2,968 | $4.87 | $14.45K | 217,216 |
| Christian O. Henry See Remarks | Mar 4, 2024 | Sale | −14,177 | $4.87 | $69.04K | 2,596,670 |
| Susan G. Kim See Remarks | Mar 4, 2024 | Sale | −5,275 | $4.87 | $25.69K | 712,260 |
| Marshall Mohr Director | Mar 1, 2024 | Option exercise | +25,000 | $4.45 | $111.25K | 110,000 |
| Susan G. Kim See Remarks | Feb 22, 2024 | Award | +432,692 | – | – | 715,450 |
| Oene Mark Van See Remarks | Feb 22, 2024 | Award | +798,076 | – | – | 1,674,687 |
| Jeff Eidel See Remarks | Feb 22, 2024 | Award | +461,538 | – | – | 893,362 |
| Michele Farmer See Remarks | Feb 22, 2024 | Award | +115,384 | – | – | 216,548 |
| Christian O. Henry See Remarks | Feb 22, 2024 | Award | +1,605,769 | – | – | 2,610,847 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Pacific Biosciences of California's stock actually held short. Settlement fails (shares not delivered on time) peaked at 71,614 shares on Sep 30, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jim Gibson Officer | Oct 6, 2026 | 661,815 | $1.90M | Oct 6, 2026 | Exercise of Stock Options |
| Oene Mark Van Officer | Aug 17, 2026 | 26,911 | $30.51K | Aug 17, 2026 | Restricted Stock |
| James R. Gibson II Officer | Apr 1, 2026 | 88,185 | $120.78K | Apr 1, 2026 | Restricted Stock |
| Christian O. Henry Officer | Mar 3, 2026 | 12,497 | $18.92K | Mar 3, 2026 | Restricted Stock |
| Oene Mark Van Officer | Mar 3, 2026 | 6,504 | $9.85K | Mar 3, 2026 | Restricted Stock |
| Christian O. Henry Officer | Feb 17, 2026 | 606,312 | $955.55K | Feb 17, 2026 | Restricted Stock |
| Oene Mark Van Officer | Feb 17, 2026 | 303,739 | $478.69K | Feb 17, 2026 | Restricted Stock |
| Oene Mark Van Officer | Aug 18, 2025 | 26,836 | $35.17K | Aug 18, 2025 | Restricted Stock |
| Oene Mark Van Officer | Mar 3, 2025 | 6,486 | $9.12K | Mar 3, 2025 | Restricted Stock |
| Christian O. Henry Officer | Mar 3, 2025 | 12,497 | $17.58K | Mar 3, 2025 | Restricted Stock |
| Oene Mark Van Officer | Feb 18, 2025 | 100,773 | $189.25K | Feb 18, 2025 | Restricted Stock |
| Christian O. Henry Officer | Feb 18, 2025 | 259,909 | $488.11K | Feb 18, 2025 | Restricted Stock |
| Oene Mark Van Officer | Jan 10, 2025 | 34,405 | $69.98K | Jan 10, 2025 | Restricted Stock |
| Susan G. Kim Officer | Sep 30, 2024 | 19,782 | $34.06K | Sep 30, 2024 | Restricted Stock |
| Christian O. Henry Officer | Sep 16, 2024 | 98,907 | $172.74K | Sep 16, 2024 | Restricted Stock |
See a number that looks wrong?